Prostaglandin endoperoxides (PGG2/PGH2), precursors of thromboxane (TX) A2 and prostaglandins, may accumulate sufficiently in the presence of a TXA2 synthase inhibitor to exert biological activity. To address whether this modulates the response to TXA2 synthase inhibition in the setting of thrombosis in vivo, we examined the interaction of a TXA2 synthase inhibitor (U63,557a) and a TXA2/prostaglandin endoperoxide receptor antagonist (L636,499) in a canine model of coronary thrombosis after electrically induced endothelial injury. U63,557a exerted little inhibitory effect in this model despite a marked reduction in serum TXB2 and urinary 2,3-dinor-TXB2, an index of TXA2 biosynthesis. Combination of the two drugs was more effective than either drug alone. The enhanced effect achieved upon addition of the TXA2/prostaglandin endoperoxide receptor antagonist to the TXA2 synthase inhibitor suggests that the response to the latter compound was limited by the proaggregatory effects of prostaglandin endoperoxides. The increased effect of the combination over the receptor antagonist alone may reflect metabolism of PGG2/PGH2 to platelet inhibitory prostaglandins. This is supported by the following findings: (a) urinary 2,3-dinor-6-keto-PGFia, an index of prostacyclin biosynthesis, increased after administration of the synthase inhibitor, an effect that was exaggerated in the presence of thrombosis; (b) inhibition of arachidonate-induced platelet aggregation by U63,557a was dependent on the formation of a platelet-inhibitory prostaglandin; and (c) pretreatment with aspirin abolished the synergism between these compounds. These studies demonstrate that prostaglandin endoperoxides modulate the response to TXA2 synthase inhibition in vivo and identify a drug combination of potential therapeutic efficacy in the prevention of thrombosis.
Introduction
Thromboxane (TX) A2, the major cyclooxygenase product of arachidonic acid in platelets, is a potent platelet aggregant and vasoconstrictor (1) and plays a pathogenic role in a variety of ischemic heart disease syndromes (2) (3) (4) (5) (6) . A reduction in TXA2 biosynthesis may be achieved by inhibition of TXA2 synthase, the enzyme that catalyses the conversion of prostaglandin endoperoxides (PGG2/PGH2) to TXA2 (7) (8) (9) . This has a theoretical advantage over cyclooxygenase inhibition, most com-monly achieved with aspirin, in that it preserves prostacyclin (PGI2) biosynthesis (7) (8) (9) . PGI2 is a major cyclooxygenase product of arachidonic acid in vascular endothelium and is a potent platelet inhibitor and vasodilator (10) . Evidence from experimental studies suggests that PGI2 limits platelet activation in vivo (11, 12) . Furthermore, PGI2 biosynthesis is increased in conditions associated with platelet activation, including severe atherosclerosis (13), unstable angina (2) , and systemic sclerosis (14) . Coincident inhibition of PGI2 formation, therefore, may limit the therapeutic response to aspirin and other cyclooxygenase inhibitors. In contrast, TXA2 synthase inhibitors do not inhibit PGI2 biosynthesis (7) (8) (9) .
Despite their biochemical selectivity, TXA2 synthase inhibitors are weak platelet inhibitors in vitro (7, [15] [16] [17] and exert variable effects in vivo (18) (19) (20) (21) . This may reflect the continued formation of platelet prostaglandin endoperoxides that activate a receptor, shared with TXA2, mediating platelet activation and vasoconstriction (7, 15, 17) . Indeed, the antiplatelet effects of TXA2 synthase inhibitors may be largely mediated through platelet-inhibitory prostaglandins formed by the metabolism of accumulated prostaglandin endoperoxides. Marcus et al., and Schafer et al., have demonstrated that, in the presence of a TXA2 synthase inhibitor, platelet-derived prostaglandin endoperoxides may be metabolized by contiguous endothelium to PGI2 (22, 23) . Other products, including PGE2 and PGD2, may also be formed and mediate the platelet effects of TXA2 synthase inhibitors (24, 25) . Pharmacologic studies have also implied a role for vascular-derived prostaglandins in mediating the response to TXA2 synthase inhibition in vivo (11, 26) . Thus, prostaglandin endoperoxides may modulate the response to TXA2 synthase inhibitors, both by substituting for the proaggregatory effects of TXA2 and through their metabolism to platelet-inhibitory prostaglandins.
To determine if these mechanisms influence thrombogenesis in vivo, we have examined the interaction of a TXA2 synthase inhibitor and an antagonist ofthe shared TXA2/prostaglandin endoperoxide receptor in a canine model of coronary artery thrombosis (27, 28) . These studies demonstrate biochemical and functional evidence of a role for prostaglandin endoperoxides in modulating the response to TXA2 synthase inhibitors in vivo and identify an interaction of potential therapeutic importance between these classes of drugs.
Methods
Animal studies Acute experiments. All animal studies were reviewed and approved by the Animal Care Committee at Vanderbilt University. Male mongrel dogs (17-23 kg) were anesthetized with pentobarbitone 30 mg/kg and ventilated using a Harvard respirator (Harvard Apparatus Co., Natick, MA). The circumflex coronary artery was isolated through a left thoracotomy and all branches ligated down to the first obtuse marginal branch. A needle electrode was passed through the arterial wall such that 4-5 mm of exposed wire lay against the endothelium, as pre-viously described (27, 28) . The electrode consisted of 30-gauge Teflon coated silver wire onto the end ofwhich was crimped the tip (2 mm) of a 28-gauge hypodermic needle to aid passage through the vessel wall. The electrode was connected in series with a 50,000 Q potentiometer, a 20,000 Q resistor, an ammeter and the positive terminal of a 9-V battery, and the circuit was grounded to the subcutaneous tissues ofthe dog. An electromagnetic flow probe (Carolina Instruments, King, NC) was positioned proximal to the electrode site and connected to an electromagnetic flowmeter (SP 2202; Gould-Statham Instrument Co., Inc., Hato Rey, Puerto Rico). Blood pressure was recorded through a polyethylene catheter implanted in the femoral artery. Coronary blood flow and femoral artery pressure were recorded continuously throughout the experiment using a strip chart recorder (HP 1758A; Hewlett Packard Co., Waltham, MA).
Animals were randomized to one of four treatments. Group I animals received vehicle only and acted as controls. In group II, the TXA2 synthase inhibitor, 5-(3'-pyridinylmethyl) benzfuran-2-carboxylate (U63,557a), was administered in a bolus dose of 10 mg/kg i.v. in normal saline over 10 min. In group III, the TXA2/prostaglandin endoperoxide receptor antagonist, 3-carboxyl-dibenzo (b,f) thiepin-5,5-dioxide (L636,499), was administered in a bolus dose of 20 mg/kg followed by 2 mg/kg per min. In group IV, both U63,557a and L636,499 were administered in these doses.
After a stabilization period of 30 after complete coronary occlusion. Urine was collected by catheterization before drug administration and hourly thereafter for measurement of2,3-dinor-TXB2 and 2,3-dinor-6-keto-prostaglandin (PG) Fl', major urinary metabolites of TXA2 and PGI2, respectively (29, 30) .
Platelet aggregation studies
Platelet aggregation to arachidonic acid (0.075-0.66 mM) (Sigma Chemical Co., St. Louis, MO) and to the endoperoxide analogue, (1 5S)-hydroxy 11 ,9-(epoxymethano)-prostadienoic acid (U46619, 0.13-2.0 AM) (Upjohn Co., Kalamazoo, MI) was determined in platelet-rich plasma (PRP) by light transmission (31), using a multichannel aggregometer (Biodata PAP4, Biodata, Hartboro, PA). PRP was prepared by centrifuging citrated venous blood (3.8% Na citrate, 9:1 vol/ vol) at 3,000 rpm for 50 s and adjusted to 300,000 platelets/Al with platelet-poor plasma obtained by centrifuging the remaining blood at 3,000 rpm for 10 Biochemical studies Urinary 2,3-dinor TXB2 and 2,3-dinor-6-keto PGF1" were determined by gas chromatography, negative ion-chemical ionization, mass spectrometry using their respective tetradeuterated analogues as internal standards (30, 33) . Briefly, to a 5-ml sample of urine was added 5 ng of each internal standard and the urine extracted by immunoaffinity chromatography as previously described (34 Platelet studies. Platelet aggregation to the TXA2/prostaglandin endoperoxide analogue, U46619, and to arachidonic acid was unaltered in control experiments (Figs. 3 and 4) . L636,499 inhibited the response to U46619 and arachidonic acid, increasing the threshold concentration of arachidonic acid for complete, irreversible aggregation from 0.23±0.02 to 0.77±0.09 mM (n = 16, P < 0.001). Combination ofU63,557a and L636,499 exerted a more marked effect, completely abolishing the response to both U46619 and arachidonic acid.
In contrast, U63,557a alone had no effect on U46619-induced platelet aggregation. The effect of U63,557a on arachidonate-induced platelet aggregation was dependent on the concentration of the agonist. Thus, inhibition of platelet aggregation was paradoxically greater at higher concentrations of arachidonic acid with no inhibition demonstrated at 0.08 and 0.17 mM arachidonic acid (Fig. 4) . This effect also occurred in vitro and was demonstrable with a structurally distinct TXA2 synthase inhibitor, imidazo [1, pyridine-5-hexanoic acid (CGS13080) (Fig. 5) (7, (15) (16) (17) (18) (19) (20) (15, 44) . In vitro studies demonstrate that prostaglandin endoperoxides can substitute for the proaggregatory effect of TXA2 and overcome the effect of TXA2 synthase inhibition on platelets (7, (15) (16) (17) . In view of the marked inhibition of TXA2 biosynthesis at doses of U63,557a used in this study, these data are consistent with the hypothesis that prostaglandin endoperoxides also limit the response to TXA2 synthase inhibition in vivo. This study also demonstrated that addition of the TXA2 synthase inhibitor increased the response to the TXA2/prostaglandin endoperoxide receptor antagonist. In part this may reflect a reduction in agonist formation. Alternatively, it may be due to increased biosynthesis of platelet inhibitory prostaglandins. In vitro studies have demonstrated that prostaglandin endoperoxides derived from platelets in the presence of a TXA2 synthase inhibitor may be metabolized or shunted to platelet-inhibitory prostaglandins, including PGI2 (22, 23) and PGD2 (24, 25), by contiguous tissues and by the isomerase activity of plasma albumin, respectively. Indeed, this may be a major mechanism of their activity both in vitro (25) and in vivo (11) . As evidence of a shunt to platelet inhibitory prostaglandins, there was a marked increase in PGI2 formation, coincident with the inhibition of TXA2 biosynthesis in animals treated with U63,557a alone or in combination with the TXA2/prostaglandin endoperoxide receptor antagonist. This effect was most marked during induction of coronary thrombosis. Furthermore, the enhanced effect seen when U63,557a was combined with L636,499 was abolished by aspirin at a dose that prevented the increase in PGI2 biosynthesis. These data, therefore, provide both functional and biochemical evidence of a shunt to platelet-inhibitory prostaglandins in the presence of a TXA2 synthase inhibitor. Similar findings have recently been reported in human volunteers by Gresele and co-workers (26) . In their studies, addition of a TXA2 synthase inhibitor enhanced the effect of a TXA2/prostaglandin endoperoxide receptor antagonist on bleeding time, an effect that was prevented by pretreatment with indomethacin.
The results of ex vivo platelet aggregation studies were also consistent with a role for platelet inhibitory prostaglandins in mediating the antiplatelet effects of U63,557a. Thus, inhibition ofarachidonate-induced platelet aggregation by U63,557a was dependent on the concentration of arachidonic acid. At 0.08-0.17 mM arachidonic acid, U63,557a failed to inhibit platelet aggregation, consistent with the proaggregatory effects of prostaglandin endoperoxides. At higher concentrations of arachidonic acid, platelet activation was inhibited in the presence of U63,557a. This was also demonstrated with a second TXA2 synthase inhibitor, CGS 13080, suggesting that it was a specific effect of this class of compounds. After incubation of platelets with a high concentration of arachidonic acid and U63,557a, platelets failed to respond to ADP or U46619. This effect was not seen at lower concentrations of arachidonic acid and was prevented by pretreating the platelets with aspirin.
These findings suggest that platelet inhibition in this setting is due to formation of a cyclooxygenase product. Similar findings have been reported using human platelets. Indeed, inhibition of arachidonate-induced aggregation of human platelets by TXA2 synthase inhibitors in vitro has been reported to largely reflect conversion of prostaglandin endoperoxides to PGD2 by the isomerase activity of plasma proteins (24, 25 
